Clinical Trial: Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC

U.S., June 14 -- ClinicalTrials.gov registry received information related to the study (NCT07018947) titled 'Study to Evaluate the Efficacy and Safety of Atezolizumab and Bevacizumab as Neoadjuvant Plus Adjuvant Treatment in HCC' on May 27.

Brief Summary: Study to evaluate the efficacy and safety of the combination of Atezolizumab and Bevacizumab as neoadjuvant plus adjuvant treatment in Hepatocellular Carcinoma.

Study Start Date: Nov., 2025

Study Type: INTERVENTIONAL

Condition: Resectable Hepatocellular Carcinoma

Intervention: DRUG: Atezolizumab and Bevacizumab

Participants will receive up to three 3 atezolizumab doses (days 10, 31, 52) and 2 bevacizumab dose (days 10 and 31) until surgery or unacceptable toxicity, whichever occurs...